Charming Medical Limited (MCTA) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 14, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2026, filed Jul 30, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MCTA SEC filings page.
Charming Medical Limited (MCTA) reported $4.8M in revenue for fiscal year 2026, down 22.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Scored against operating companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Charming Medical Limited's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Charming Medical Limited has an operating margin of -0.6%, meaning the company loses $1 on every $100 of revenue. This results in a profitability score of 59/100. This is down from 22.3% the prior year.
Charming Medical Limited's revenue declined 22.7% year-over-year, from $6.2M to $4.8M. This contraction results in a growth score of 9/100.
Charming Medical Limited carries a low D/E ratio of 0.04, meaning only $0.04 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
Charming Medical Limited's current ratio of 1.89 indicates adequate short-term liquidity, earning a score of 56/100. The company can meet its near-term obligations, though with limited headroom.
Charming Medical Limited's operations used $1.2M of cash, and capex of $340K added to the outflow, for a free cash flow shortfall of $1.6M. This results in a cash flow score of 9/100.
Charming Medical Limited posts a -0.4% return on equity (ROE), meaning it loses less than $1 for every $100 of shareholders' equity. This results in a returns score of 80/100. This is down from 2435.0% the prior year.
Charming Medical Limited scores 57.99, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($445.6M) relative to total liabilities ($4.7M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Charming Medical Limited passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). No profitability signals pass, all 1 leverage/liquidity signals pass, neither operating efficiency signal passes.
Charming Medical Limited reported a net loss of $23K while operations used $1.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Charming Medical Limited reported an operating loss of $29K against $16K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2026.
Cash & Balance Sheet
Charming Medical Limited held $4.7M in cash against $186K in long-term debt as of Q4 2026.
Not reported for Q4 2026.
Not reported for Q4 2026.
Margins & Returns
None of these metrics is reported for Q4 2026.
Capital Allocation
None of these metrics is reported for Q4 2026.
MCTA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
MCTA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2620-F | Q4'2520-F |
|---|---|---|
| Total Assets | $9.9M+84.3% | $5.4M |
| Current Assets | $8.2M+142.8% | $3.4M |
| Cash & Equivalents | $4.7M+475.3% | $817K |
| Short-Term Investments | $1.3M | $0 |
| Inventory | $26K-4.4% | $27K |
| Accounts Receivable | $201K-49.1% | $396K |
| Long-Term Investments | $0 | $0 |
| Total Liabilities | $4.7M-11.7% | $5.3M |
| Current Liabilities | $4.3M-12.5% | $4.9M |
| Non-Current Liabilities | $356K-0.7% | $358K |
| Long-Term Debt | $186K | N/A |
| Total Equity | $5.2M+10421.2% | $49K |
| Retained Earnings | $97K-19.0% | $119K |
Not reported in any period shown, so not listed: Goodwill.
MCTA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
MCTA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.
Where Charming Medical Limited Ranks
Frequently Asked Questions
What is Charming Medical Limited's annual revenue?
Charming Medical Limited (MCTA) reported $4.8M in total revenue for fiscal year 2026. This represents a -22.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Charming Medical Limited's revenue growing?
Charming Medical Limited (MCTA) revenue declined by 22.7% year-over-year, from $6.2M to $4.8M in fiscal year 2026.
Is Charming Medical Limited profitable?
No, Charming Medical Limited (MCTA) reported a net income of -$23K in fiscal year 2026, with a net profit margin of -0.5%.
What is Charming Medical Limited's EBITDA?
Charming Medical Limited (MCTA) had EBITDA of $187K in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Charming Medical Limited have?
As of fiscal year 2026, Charming Medical Limited (MCTA) had $4.7M in cash and equivalents against $186K in long-term debt.
What is Charming Medical Limited's gross margin?
Charming Medical Limited (MCTA) had a gross margin of 99.3% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.
What is Charming Medical Limited's operating margin?
Charming Medical Limited (MCTA) had an operating margin of -0.6% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.
What is Charming Medical Limited's net profit margin?
Charming Medical Limited (MCTA) had a net profit margin of -0.5% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.
What is Charming Medical Limited's return on equity (ROE)?
Charming Medical Limited (MCTA) has a return on equity of -0.4% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is Charming Medical Limited's free cash flow?
Charming Medical Limited (MCTA) recorded an outflow of $1.6M in free cash flow during fiscal year 2026. This represents a -1224.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Charming Medical Limited's operating cash flow?
Charming Medical Limited (MCTA) recorded an outflow of $1.2M in operating cash flow during fiscal year 2026, representing cash used by core business activities.
What are Charming Medical Limited's total assets?
Charming Medical Limited (MCTA) had $9.9M in total assets as of fiscal year 2026, including both current and long-term assets.
What are Charming Medical Limited's capital expenditures?
Charming Medical Limited (MCTA) invested $340K in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
What is Charming Medical Limited's current ratio?
Charming Medical Limited (MCTA) had a current ratio of 1.89 as of fiscal year 2026, which is generally considered healthy.
What is Charming Medical Limited's debt-to-equity ratio?
Charming Medical Limited (MCTA) had a debt-to-equity ratio of 0.04 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Charming Medical Limited's return on assets (ROA)?
Charming Medical Limited (MCTA) had a return on assets of -0.2% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is Charming Medical Limited's P/E ratio?
Charming Medical Limited (MCTA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2026). The market capitalization is $445.6M as of Sep 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Charming Medical Limited's price-to-sales ratio?
Charming Medical Limited (MCTA) trades at 92.7x sales, its market capitalization divided by revenue of $4.8M revenue, FY2026. The market capitalization is $445.6M as of Sep 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Charming Medical Limited's liquidity compare with its operating cash outflow?
At the end of fiscal year 2026, Charming Medical Limited (MCTA) held $6.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $1.2M over that year. Dividing the one by the other, the reported balance equals about 59 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Charming Medical Limited's Altman Z-Score?
Charming Medical Limited (MCTA) has an Altman Z-Score of 57.99, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Charming Medical Limited's Piotroski F-Score?
Charming Medical Limited (MCTA) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Charming Medical Limited's earnings high quality?
Charming Medical Limited (MCTA) reported a net loss of $23K while operations used $1.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Charming Medical Limited cover its interest payments?
Charming Medical Limited (MCTA) reported an operating loss of $29K against $16K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Charming Medical Limited?
Charming Medical Limited (MCTA) scores 52 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.